Drug Type Small molecule drug |
Synonyms Eolo 40 |
Target |
Action inhibitors |
Mechanism NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Preclinical | United States | 21 Jun 2024 | |
Amyotrophic Lateral Sclerosis | Preclinical | United States | 21 Jun 2024 |